Human Microbiome Articles & Analysis
50 news found
A surge in research projects on the human microbiome - the complex ecosystem of microorganisms in the human gastrointestinal tract - is bolstering scientific understanding of health, disease and environment. ...
(KINS), a company with a database of human microbiome, for the Collaborative Lab, a collaborative research facility for startups, which was established in a new research laboratory at the "JSR Bioscience and Informatics R&D Center (JSR BiRD)" in Kawasaki City, Kanagawa Prefecture last July. ...
About SER-155 SER-155, an oral consortium of cultivated bacteria, is a microbiome therapeutic candidate in clinical development. SER-155 is designed using microbiome biomarker data from human clinical data, human cell-based assays, and in vivo disease models, with the aim to decrease infection and translocation of ...
"Joining the AOBiome team is an exciting opportunity to advance the application of ammonia oxidizing bacteria to the treatment of human disease. Reestablishing the symbiotic relationship between bacteria and human to restore important biologic and biochemical processes is a growing area in science and medicine. ...
About Vedanta Biosciences Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile ...
In colon organoids – microscopic 3D collections of human cells that function as a tiny colon – SER-155 blocked several key inflammatory gene expression pathways linked with GvHD. ...
--(BUSINESS WIRE)--May 4, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. ...
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis ...
ByBio-Me
(California, USA) to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome. Microviable expertise on gut microbiome research will enable to conveniently process microbiota samples for fermentation applications that coupled with BCD Bioscience advance prebiotics platform will open new avenues into ...
With years of experience in the pharmaceutical and life science sectors, CD Genomics has announced Microbial Transcriptomics solutions, which hold promise in uncovering novel ways to treat disease and improve human health. The transcriptome is the complete set of RNAs encoded by an organism's genome. ...
The international investment syndicate was co-led by Flerie Invest, a major Swedish life science investor focussing on companies with ambitious science and the ability to tackle major medical challenges, and Tencent, a global technology company investing in innovations that help improve human life. New investors also included British Patient Capital, while existing investors ...
City of Hope, one of the largest cancer research and treatment organizations in the United States, and Osel Inc., a company developing live biotherapeutic products for modulation of the human microbiome, today announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 (Clostridium butyricum MIYAIRI 588® strain) plus immunotherapy medicine ...
About Vedanta Biosciences Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile ...
The bacterial communities on the human body surface and in the body are becoming an important source of personalized medicine. ...
(“AOBiome”), a leading clinical-stage microbiome company focusing on inflammatory conditions, has announced the completion of a cosmetic study investigating the safety and effects of its novel AOB formulation on subjects with mild to moderate eczema. ...
City of Hope®, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that City of Hope has granted an exclusive worldwide license to Osel for ...
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine • EO2463 combines four microbiome-peptides of B lymphocytes-specific lineage markers designed to induce the full depletion of malignant B lymphocytes ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular ...
ByEnterome
Nelson joined Thermo Fisher on July 6. Nelson who pioneered the human microbiome field, received her Ph.D. from Cornell University. She has authored or co-authored more than 220 peer reviewed publications, edited three books and is currently editor-in-chief of the journals Microbial Ecology and the newly formed PNAS Nexus. ...
The new data were presented at the International Human Microbiome Consortium Congress 2021 (IHMC), being held virtually from June 27-29th. ...
Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced today that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented data from a Phase 1b trial showing that an LBP, CBM588 (Clostridium butyricum MIYAIRI 588® strain), plus ...